Optiscan Imaging Limited
Appendix 4D
Half-year report
1. Company details
Name of entity: | Optiscan Imaging Limited | ||||
ABN: | 81 077 771 987 | ||||
only | For the half-year ended 31 December 2021 | ||||
Reporting period: | |||||
Previous period: | For the half-year ended 31 December 2020 | ||||
2. Results for announcement to the market | |||||
$ | |||||
Revenues from ordinary activities | up | 4.2% | to | 555,789 | |
use | |||||
Loss from ordinary activities after tax attributable to the owners of | |||||
Optiscan Imaging Limited | up | 156.3% | to | (1,926,957) | |
Lo for the half-year attributable to the owners of Optiscan Imaging | |||||
Limited | up | 156.3% | to | (1,926,957) | |
Dividends | |||||
There were no dividends paid or declared during the current financial period. | |||||
personal | |||||
Comments |
The loss for the consolidated entity after providing for income tax amounted to $1,926,957 (31 December 2020: $751,715).
Fin ncial performance
During the 6 month period to 31 December 2021 (H1FY22), the consolidated entity generated ordinary revenue of $555,789 from sales, system rentals and the provision of services, compared to $533,574 in the previous corresponding period.
The consolidated entity also recorded research and development incentive income for H1FY22 $594,669, an increase of $305,029 from the previous corresponding period (2021: $289,640). Income of $279,255 for H1FY22 was recorded from the BioMedTech Horizons program grant, which was an increase of $29,686 from the previous corresponding period (2021: $249,569).
Total expenses for H1FY22, excluding research and development and intellectual property expenses, were $2,016,343, an incr ase of $843,873 from the corresponding period (2020: $1,172,470). Research and development and intellectual property
xp nses were $1,367,056, an increase of $701,217 from the previous corresponding period of $665,839.
Financial position
The net assets decreased by $1,505,171 to $8,711,935 at 31 December 2021 (30 June 2021: $10,217,106) primarily due expenditure on the consolidated entity's operational activities and working capital requirements.
ForThe working capital position of the consolidated entity as at 31 December 2021 resulted in an excess of current assets over current liabilities of $8,531,561 (30 June 2021: $9,995,498).
Net cash used in operating activities was $1,328,241, an increase of $1,152,204 compared to the corresponding period (2021: operating cash outflows of $176,037).
3. Net tangible assets | |||
Reporting | Previous | ||
period | period | ||
Cents | Cents | ||
Net tangible assets per ordinary security | 1.42 | 1.67 | |
Optiscan Imaging Limited
Appendix 4D
Half-year report
The net tangible assets per ordinary security has been calculated excluding the Right of use asset amount.
4. | Control gained over entities | |
only | ||
Not applicable. | ||
5. | Loss of control over entities | |
N | t applicable. | |
6. | Dividends | |
use |
Current period
There were no dividends paid or declared during the current financial period.
Previous period
There were no dividends paid or declared during the previous financial period.
7. Dividend reinvestment plans personalNot applicable.
8. Details of associates and joint venture entities Not applicable.
9. Foreign entities
Details of origin of accounting standards used in compiling the report:
Not applicable.
10. Audit qualification or review
Details of audit/review dispute or qualification (if any):
ForThe financial statements were subject to a review by the auditors and the review report is attached as part of the Interim Report.
11. Attachments
Details of attachments (if any):
The Interim Report of Optiscan Imaging Limited for the half-year ended 31 December 2021 is attached.
Optiscan Imaging Limited Appendix 4D
Half-year report 12. Signed
personalForuse only | Date: 24 February 2022 |
Signed ___________________________ | |
Robert Cooke | |
Non-executive Chairman |
onlyOptiscan Imaging Limited
ABN 81 077 771 987
useInterim Report - 31 December 2021 personalFor
Optiscan Imaging Limited Corporate directory
31 December 2021
Directors
onlyCompany secretary Registered office
Principal place of business
useShare register
Auditor
personalStock exchange listing Website
For
Mr Robert Cooke (Non-executive Chairman)
Prof Camile Farah (Managing Director)
Ms Karen Borg (Non-executive Director)
Mr Ron Song (Non-executive Director)
Mr Justin Mouchacca
16 Miles Street
Mulgrave, Victoria, 3170
Phone No.: (03) 9598 3333
Fax No.: (03) 9562 7742
16 Miles Street
Mulgrave, Victoria, 3170
Phone No.: (03) 9598 3333
Fax No.: (03) 9562 7742
Computershare Investor Registry Services
Yarra Falls
452 Johnston Street
Abbotsford, Victoria, 3067
Phone No.: (03) 9415 5000
Grant Thornton Audit Pty Ltd
Collins Square, Tower 5,
727 Collins Street, Melbourne VIC 3008
Australia
Optiscan Imaging Limited securities are listed on the Australian Securities Exchange (ASX code: OIL)
www.optiscan.com
1
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Optiscan Imaging Limited published this content on 24 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 February 2022 06:31:08 UTC.